Richard Kuo
CEO
Wobble Genomics
Wobble Genomics develops advanced computational tools for analyzing complex genomic datasets. The platform provides researchers with high-throughput sequence alignment and variant calling capabilities. This accelerates discovery in areas like personalized medicine and disease mechanism identification.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$13.2MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Current methods for detecting cancer biomarkers in blood face challenges in identifying low-abundance RNA sequences, which can be critical for early and accurate disease detection. Existing technologies often miss these subtle signals due to the overwhelming presence of highly abundant RNA from housekeeping genes. This limitation hinders the ability to effectively monitor disease status and make informed treatment decisions for cancer patients.
Solution
Wobble Genomics offers a diagnostic platform that leverages long-read RNA sequencing and proprietary technologies, Level-Up and TAMA, to detect low-abundance, full-length RNA from whole blood. The Level-Up technology enhances the representation of these rare RNA sequences, enabling the identification of novel nucleic acid biomarkers. TAMA, a bioinformatic pipeline, optimizes the identification of low-level signals within the sequencing data. By combining these technologies, Wobble Genomics can build comprehensive transcriptome profiles from liquid biopsies, separating cancer-associated RNA sequences from those of healthy individuals. This approach provides more accurate disease status information and enables the discovery of new biomarkers for cancer.
Target Audience
The primary audience includes oncologists, researchers, and pharmaceutical companies focused on cancer diagnostics, disease monitoring, treatment planning, and drug development.
Features
- Level-Up technology: A biochemical method to increase the representation of low-abundance RNA sequences in samples.
- TAMA: A bioinformatic pipeline that optimizes the identification of low-level signals in long-read RNA sequencing data.
- Full-length RNA sequencing: Provides comprehensive transcriptome profiles from liquid biopsies.
- Biomarker discovery: Identifies novel nucleic acid biomarkers for cancer detection and monitoring.
- Early-stage cancer detection: Demonstrated 80% sensitivity at 95% specificity for early-stage breast cancer detection in a clinical study.
- Database of novel transcripts: Building a database of newly discovered RNA transcripts to characterize human disease and identify biomarkers.